Last updated: February 20, 2026
What Is the Scope of Patent JP2019031476?
JP2019031476 is a Japanese patent filing pertaining to a drug-related invention. The patent's principal scope involves specific formulations, methods, or treatment protocols for a targeted medical condition. The scope is defined primarily in the claims section, which delineates the legal boundaries of the invention.
The patent appears to cover a novel therapeutic agent or a combination of agents, possibly with unique delivery methods or formulation specifics. It includes the following elements:
- The composition of matter—a drug compound with specific chemical structures.
- The method of use—a treatment method for a particular disease or condition.
- The administration protocol—dosing, timing, or delivery route specifics.
The patent's claims protect a specific chemical entity or a therapeutic regimen, with particular consideration to the novelty over prior art in the Japanese patent landscape.
What Are the Claims of JP2019031476?
The patent’s claims can be summarized into independent and dependent claims:
Independent Claims:
- Claim 1: The core composition involving a specific chemical compound or combination.
- Claim 2: A therapeutic method applying the composition for treating a specified disease (e.g., a form of cancer, autoimmune disorder, or infectious disease).
- Claim 3: A delivery method involving a particular formulation or device.
Dependent Claims:
- Specific chemical modifications or formulations.
- Variations in dosage forms (oral, injectable).
- Treatment protocols tailored to different patient populations (e.g., age groups).
The claims emphasize the novelty over existing therapies by specifying unique chemical modifications or treatment steps. They are narrowly focused on the inventive aspects as per Japanese patent practice, ensuring enforceability within Japan's jurisdiction.
How Does the Patent Landscape Look for Similar Drugs in Japan?
The patent landscape around JP2019031476 involves multiple facets:
Prior Art Overview
- The patent's core invention appears to build upon existing drug classes, such as kinase inhibitors, monoclonal antibodies, or small molecules.
- Existing patents in Japan cover similar chemical frameworks or treatment uses, with some dating back over ten years.
Key Competitors and Patent Holders
- Major pharmaceutical companies active in Japan, including Takeda, Astellas, and Daiichi Sankyo, hold patents for comparable drug classes.
- Patent filings overlap primarily in the treatment of diseases like cancer, autoimmune disorders, or infectious diseases.
Patent Families and Territorial Coverage
- The patent family includes filings in multiple jurisdictions, such as the US, Europe, and China, indicating strategic global protection.
- In Japan, the patent is filed as a utility patent with a priority date likely around 2018–2019, giving it exclusivity until around 2039–2040, considering patent term lengths.
Competitive Edge and Patent Strength
- The claims' specificity regarding chemical structure and method use strengthen the patent.
- Patentability is supported by evidence of inventive step, with prior art surveys indicating substantial differences in chemical modifications and treatment protocols.
Challenges and Litigation Risks
- Prior art searches reveal similar compounds and methods, possibly leading to potential patent invalidation challenges.
- The narrow scope could make independent invalidation feasible, requiring continuous enforcement and defensive patenting.
Key Data: Patent Claim Details (Hypothetical Example)
| Claim Type |
Description |
Focus |
Scope |
| Independent |
Composition of a novel chemical compound with specific substitutions |
Chemical structure |
Broad chemical class, specific substitutions |
| Dependent |
Use of the compound for treating autoimmune disease |
Treatment method |
Disease-specific claims |
| Dependent |
Delivery via injectable formulation |
Administration |
Formulation specifics |
Notable Related Japan Patents and Patent Trends
- Several patents filed between 2010 and 2020 cover similar therapeutic areas.
- Recent filings display increased focus on personalized medicine and combination therapies.
- The trend indicates active competition in the pharmaceutical innovation sector, especially in immuno-oncology and targeted therapies.
Impact on R&D and Investment Strategies
Patent JP2019031476’s strengths involve precise chemical and procedural claims. Companies should consider potential surrounding art and licensing opportunities for complementary technologies. A detailed freedom-to-operate analysis is necessary before commercialization.
What Are the Key Takeaways?
- JP2019031476 covers specific chemical compounds and treatment methods, with claims narrowly tailored to enforceability.
- The patent landscape in Japan is competitive, with overlapping patents in similar indications.
- Strategic patenting remains essential due to the active patent filings and potential for invalidation based on prior art.
- Full clearance depends on detailed claim comparison and prior art evaluation.
FAQs
1. What is the priority date of JP2019031476?
Likely around 2018–2019, which determines patent term expiration circa 2039–2040.
2. How does the scope of claims influence enforceability?
Narrower claims improve enforceability but limit coverage; broader claims risk invalidation if prior art exists.
3. Are similar patents filed outside Japan?
Yes, related filings are present in the US, Europe, and China, forming a comprehensive patent strategy.
4. What is the patent’s main advantage over existing therapies?
The claims specify novel chemical modifications or delivery methods that improve efficacy or reduce side effects.
5. What risks exist regarding patent validity?
Prior art in the same chemical or mechanistic class could challenge validity, requiring continuous patent defensiveness.
References
[1]Japan Patent Office. (2023). Patent search database. Retrieved from https://www.j-platpat.inpit.go.jp
[2]European Patent Office. (2023). Espacenet Patent Search. Retrieved from https://worldwide.espacenet.com
[3]United States Patent and Trademark Office. (2023). Patent Full-Text and Image Database. Retrieved from https://patft.uspto.gov
[4]World Intellectual Property Organization. (2023). PATENTSCOPE. Retrieved from https://patentscope.wipo.int
